文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

重型再生障碍性贫血中替代供者造血干细胞移植作为一线治疗的空白与将证据转化为实践的机会

Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.
PubMed 文献 · Blood Adv · 2025-01-01

该综述讨论重型再生障碍性贫血(SAA)当前以抗胸腺细胞球蛋白联合环孢素为主的免疫抑制治疗(IST)与异基因造血干细胞移植(HCT)的现状,指出替代供者HCT因移植相关并发症尤其移植物抗宿主病(GVHD)曾受限,而移植后环磷酰胺等进展改善了替代供者HCT结局,但作为一线治疗仍使用不足,部分因多中心试验数据有限;文中介绍CureAA与TransIT等正在进行的临床试验可能帮助填补这些空白,并强调利益相关者参与和实施科学对将研究证据整合进临床实践的重要性。

要点

  • IST联合抗胸腺细胞球蛋白与环孢素长期为SAA一线选择,但疗效持久性有限且存在远期并发症风险。
  • 替代供者HCT既往因移植相关并发症尤其GVHD增加而受限,近年移植后环磷酰胺等进展改善了结局。
  • 替代供者HCT作为一线治疗仍使用不足,部分因多中心试验数据有限;CureAA与TransIT等试验可能帮助填补空白。

核心结论

  • 替代供者HCT作为SAA一线治疗仍使用不足,部分因多中心试验数据有限,CureAA与TransIT等正在进行的临床试验可能帮助填补这些空白。
  • 将研究证据整合进临床实践需要利益相关者参与和实施科学,以实现对既往被排除在一线HCT之外患者的公平可及。

研究设计与样本

  • 本文为综述,讨论SAA当前IST与HCT治疗方式并指出剩余空白。
  • 文中讨论CureAA与TransIT等正在进行的临床试验可能如何帮助填补这些空白。

主要发现

  • IST联合抗胸腺细胞球蛋白与环孢素长期为SAA一线治疗选择,但其疗效持久性有限且存在远期并发症如继发恶性肿瘤的风险。
  • 异基因HCT是潜在治愈选择,尤其HLA相合同胞供者长期结局显著改善。
  • 替代供者如单倍体、不全相合或相合无关供者HCT既往因移植相关并发症尤其GVHD增加而受限。
  • HCT因此曾限于年轻受者及有HLA相合同胞供者者,造成年长者及缺乏相合供者选择者的显著差异。
  • 移植后环磷酰胺用于GVHD预防等较新进展改善了替代供者HCT结局,但替代供者HCT作为一线治疗仍使用不足。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 替代供者HCT作为一线治疗仍使用不足,部分因多中心试验数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe aplastic anemia (SAA) is a rare and life-threatening bone marrow failure disorder. Immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporine has long been a frontline treatment option in SAA; however, its limited durability and risk of long-term complications such as secondary malignancies remain a drawback in this treatment modality. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option with significantly improved outcomes over the long term, particularly with HLA-matched related donors. However, the use of alternative donors, such as haploidentical, mismatched, or matched unrelated donors, has previously been limited due to increased transplant-related morbidity, particularly graft-versus-host disease (GVHD). HCTs have therefore been limited to young recipients and those with HLA-matched related donors, creating significant disparity for older adults and those who lack matched donor options. Nevertheless, more recent advances in HCT, such as posttransplant cyclophosphamide for GVHD prophylaxis, have led to improved outcomes of HCT with alternative donors; however, alternative donor HCT remains underused as up-front therapy, in part because of limited multicenter trial data. This review discusses current SAA treatment approaches, including both IST and HCT, and highlights remaining gaps. It also discusses how ongoing clinical trials such as CureAA and TransIT could help address these gaps. Furthermore, we discuss the importance of stakeholder engagement and implementation science in the integration of research-based evidence into clinical practice. Bridging these gaps is necessary for achieving equitable access for patients historically excluded from frontline HCT, including older adults and racially or ethnically diverse populations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bhatt NS, Borogovac A, Efebera YA, et al. Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice. Blood Adv. 2025. PMID: 40554428. doi:10.1182/bloodadvances.2024015405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。